SCHEMBL676181

SCHEMBL676181

CCOCn1c2ccccc2c2ccc(C#Cc3ccccc3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.42
KCNH2 Q12809 1/20 0.42
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 3/20 0.38
HPGD P15428 3/20 0.38
ALOX15 P16050 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
CYP2C19 P33261 1/20 0.38
THPO P40225 1/20 0.38
KMT2A Q03164 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676145 0.80 CYP1A2 (0.41) GRM5KDM4EALDH1A1NPC1HPGD
SCHEMBL675907 0.80 GRM5 (0.39) GRM5KCNH2KDM4EALDH1A1NPC1
SCHEMBL676114 0.80 PTGER4 (0.56) GRM5KDM4EALDH1A1HPGDALOX15
SCHEMBL674752 0.78 PTGER4 (0.49) KDM4EALDH1A1NPC1HPGDALOX15
SCHEMBL679421 0.78 L3MBTL1 (0.49) GRM5KCNH2KDM4EALDH1A1NPC1
SCHEMBL676390 0.75 SLC2A1 (0.34) GRM5KDM4EALDH1A1NPC1TP53
SCHEMBL676186 0.69 POLB (0.41) KDM4EALDH1A1NPC1HPGDALOX15
SCHEMBL13553021 0.66 MEN1 (0.49) KDM4EALDH1A1HPGDMEN1CYP1A2
SCHEMBL676791 0.66 PTGER4 (0.49) KDM4EALDH1A1HPGDALOX15TP53
SCHEMBL24609501 0.64 NPC1 (0.48) KDM4EALDH1A1NPC1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 GRM5 3229/4885KCNH2 2836/4885KDM4E 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.